Decera Clinical Education Infectious Disease Podcast – Details, episodes & analysis

In this episode, Alexander Wong, MD, FRCPC, discusses how to optimize treatment and engagement in care for individuals with HIV and substance use disorder, including: 

• Barriers to care for persons with substance use disorder 
• Colocating HIV and other services (eg, addiction care medicine, social services) 
• Leveraging a multidisciplinary approach to care 
• Integrating a low-barrier model to foster an environment of open discussion 
• Best practices for opioid agonist therapy implementation
• Considerations for cultural dynamics to provide personalized treatment plans
• Importance of supporting his team members 

Presenter

Alexander Wong, MD, FRCPC
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Saskatchewan
Regina, Saskatchewan, Canada

Link to full program:
https://bit.ly/3xicSeF

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:

• The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
• An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
• 48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
• A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV
   

Presenters:

Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California

David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania

To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  

See the full program here.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss strategies for optimizing PBC pruritus care in the clinic setting.

Listen to their conversation on how important it is to ask patients about their pruritus, validate their symptoms and feelings, and offer treatment options framed with realistic expectations.

Presenters:

Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health 
Detroit, Michigan

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
University of Texas Southwestern
Dallas, Texas

Brenda Remo
Person living with PBC

Downloadable slides: 
https://bit.ly/3LHHiuf

Program: 
https://bit.ly/4fBLQ3l

To get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Raphael J. Landovitz, MD, MSc, and Hyman Scott, MD, MPH, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: 

• Misconceptions about PrEP eligibility 
• Strategies to improve lab monitoring on PrEP 
• Leveraging patient navigators and clinic staff to expand PrEP access
• Data on PrEP efficacy in key populations (eg, transgender men, people who inject drugs)
• Considerations for prescribing on-demand and same-day PrEP 
• Addressing healthcare professional hesitancy to prescribe PrEP
• US Preventive Services Task Force PrEP guideline updates
• Bundling sexually transmitted infection services with PrEP

Faculty

Raphael J. Landovitz, MD, MSc
Professor of Medicine
Division of Infectious Diseases
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services 
Los Angeles, California

Hyman Scott, MD
Assistant Clinical Professor
Department of Medicine
University of California, San Francisco
Clinical Research Medical Director
Bridge HIV
San Francisco Department of 
Public Health
San Francisco, California

Link to full program: 
https://bit.ly/3PZGYdR

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Angela Branche, MD, discusses the Advisory Committee on Immunization Practices recommendations for RSV vaccines in older adults, including: 

• Use of shared clinical decision-making 
• How to approach the conversation about the RSV vaccine with patients
• Key populations who may benefit the most, such as those at risk for severe RSV disease (eg, increasing age and persons who are frail or have cardiopulmonary comorbidities)

Faculty: 

Angela Branche, MD

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York

Link to full program: https://bit.ly/3nb25xe

Link to downloadable slides: https://bit.ly/3nb25xe

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:

• Guideline recommendations for selecting a new ART regimen
• Options for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistance
• Data from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIV

Presenter:

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

To download the slides:
https://bit.ly/3OcqxIE

To view the full online program:
https://bit.ly/3ZjSFhg

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Oni Blackstock, MD, MHS, and Brittany Williams, PhD,discuss key considerations to pre-exposure prophylaxis (PrEP) uptake in cisgender women, including: 

• The misconception by patients and healthcare professionals (HCP) that cisgender women are at low risk for HIV 
• Reframing HIV prevention from “risks” to “reasons” such as promoting self-care and taking control of one’s own sexual health
• CDC PrEP guidance recommendations 
• Increasing PrEP awareness by sharing PrEP experiences with others in the community
• The importance of community representation in PrEP marketing and campaigns 
• Challenges with finding HCPs who prescribe PrEP for cisgender women
• Promoting self-advocacy when seeking care, including HIV prevention 
• Strategies for patients to engage with their HCPs to learn about and obtain PrEP 
• Available resources for PrEP coverage

Faculty: 

Oni Blackstock, MD, MHS
Founder & Executive Director

Health Justice

New York, New York

Brittany Williams, PhD
Assistant Professor of Higher Education and Student Affairs Administration

Department of Education

University of Vermont

Burlington, Vermont

Link to full program: https://bit.ly/3PZGYdR

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:

• Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)
• Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides 
• Identifying the target patient population
• Selecting the right location to provide long-acting lipoglycopeptides 
• Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay) 
• Key characteristics of available long-acting lipoglycopeptides 
• Addressing logistical challenges, including navigating the reimbursement process

Faculty:

Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California

Link to full program: 

• CCO: https://bit.ly/3J4mg8h
• ProCE: https://bit.ly/3P0vB4E

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joseph Ahn, MD, MS, MBA; Christina Delacruz Leyson, MD; and Alice Chan, a person who experienced pregnancy as a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in people of childbearing potential and their infants, including:

• HBV screening and vaccination in pregnancy
• Management of pregnant people who are HBsAg positive
• Infant care
• Breastfeeding

Presenters: 

Joseph Ahn, MD, MS, MBA
Professor of Medicine, Section Chief
Division of Gastroenterology and Hepatology
Oregon Health & Science University
Portland, Oregon

Christina Delacruz Leyson, MD
Associate Professor
Medical Director, Liver Transplant Program
Program Director, Hepatology Fellowship
University of Kentucky
Lexington, Kentucky

Alice Chan, person living with chronic hepatitis B

Link to downloadable slides:
https://bit.ly/3rXLTC7

Link to program: 
https://bit.ly/3L3Kz6l

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:

• The definitions of virologic blips, low-level viremia, and virologic failure on ART
• The infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real world
• The potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factors
• The impact of adherence on viral suppression with BIC- and DTG-based ART
• Drug-drug interactions as a reason for failure of first-line INSTI-based ART
• What to do if someone is experiencing virologic failure requiring an ART change
• The use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experience
• The impact of high HIV-1 RNA on ART effectiveness
• The impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ART
• Strategies to encourage and measure patient adherence to ART 

Presenters

Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts

Cristina Mussini, MD
Professor
Department of Infectious Diseases
University of Modena and 
Reggio Emilia
Modena, Italy

Link to full program: https://bit.ly/3HPu4Lk

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.